Clobetasone butyrate, a new topical corticosteroid: clinical activity and effects on pituitary-adrenal axis function and model of epidermal atrophy.
- 13 September 1975
- Vol. 3 (5984) , 626-628
- https://doi.org/10.1136/bmj.3.5984.626
Abstract
Clobetasone butyrate is a new corticosteroid, selected for study because of its combination of good activity in the vasoconstriction test and low systemic activity in animals. Formulated as an 0.05% ointment and cream (Molivate) it was clinically effective in patients with eczema, its activity being significantly greater than that of hydrocortisone 1% or fluocortolone 0.2% (Ultradil). Under conditions that predispose to maximal percutaneous absorption clobetasone butyrate ointment had minimal effect on hypothalamic-pituitary-adrenal function. In an animal model of cutaneous atrophy it caused less thinning of the epidermis than steroids other than hydrocortisone. Clobetasone butyrate 0.05% ointment and cream gave every indication of offering clinically effective topical anti-inflammatory activity with a wide margin of safety.Keywords
This publication has 5 references indexed in Scilit:
- Pustular psoriasis with adrenal suppression following topical corticosteroids.1974
- Vasoconstrictor and Systemic Activities of Topical SteroidsArchives of Dermatology, 1968
- PITUITARY-ADRENAL FUNCTION AFTER OCCLUSIVE TOPICAL THERAPY WITH BETAMETHASONE-17-VALERATEThe Lancet, 1967
- Percutaneous Absorption of Hydrocortisone in ChildrenArchives of Pediatrics & Adolescent Medicine, 1966
- BETAMETHASONE 17-VALERATE: A NEW TOPICAL CORTICOSTEROIDThe Lancet, 1964